TAK-960

Known as: PLK1 Inhibitor TAK-960, Polo-like Kinase 1 Inhibitor TAK-960 
An orally available, Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor TAK-960 selectively… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2018
01220122018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Polo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic progression. Plk1 is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
The cytotoxicity of ionizing radiation depends on the cell cycle phase; therefore, its pharmacological manipulation, especially… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2015
2015
Sarcomas are rare cancers and the current treatments in inoperable or metastatic disease have not been shown to prolong survival… (More)
Is this relevant?
2013
2013
Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in key processes during mitosis. Human PLK1 has been… (More)
Is this relevant?
2012
2012
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in key processes during mitosis. HumanPLK1has been shown… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?